Unlock instant, AI-driven research and patent intelligence for your innovation.

Recombinant dimerized antithrombin III-fc fusion protein and its high-efficiency expression system in mammalian cells

A fusion protein and cell technology, which is applied in the treatment of various coagulation-related diseases, and can solve the problems of low yield, poor stability, and extended half-life of AT derivatives, etc.

Active Publication Date: 2015-09-30
AMPSOURCE BIOPHARMA (SHANGHAI) INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] In view of the shortcomings and limitations of the preparation of AT described in the above prior art and its clinical application, such as low expression, short half-life and stable poor performance, etc., there is an urgent need to develop AT derivatives with long-acting, good stability and reduced production costs in this field
So far, there is no AT derivative AT with a significantly prolonged half-life and high-efficiency and stable expression.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant dimerized antithrombin III-fc fusion protein and its high-efficiency expression system in mammalian cells
  • Recombinant dimerized antithrombin III-fc fusion protein and its high-efficiency expression system in mammalian cells
  • Recombinant dimerized antithrombin III-fc fusion protein and its high-efficiency expression system in mammalian cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1. Construction of a gene encoding hAT-L-vFcγ fusion protein

[0084] Human AT gene was purchased from Thermo-Fisher Company. The target gene was amplified by polymerase chain reaction (PCR). In order to facilitate cloning, the oligonucleotide sequence TCAGATCCGCTAGCCGCCCACCATGGTCTCCCAGGCCCTCAGGCTC introduced into the restriction enzyme endonuclease site NheI was used as a 5' primer; the BamHI restriction endonuclease site was introduced into The dot oligonucleotide sequence GTCGAGGATCCGGGAAATGGGGCTCGCAGGAGGAC was used as the 3' primer. The human AT gene sequence was verified by DNA sequencing.

[0085] Flexible Peptide Linker and Human IgG Fc Region Fc γ 2 variant vFc γ2 (Pro331Ser mutation), Fc γ 4 variant vFc γ4 (Ser228Pro and Leu235Ala mutations), Fc γ 1 variant vFc γ1 (Leu234Val, Leu235Ala, and Pro331SSer mutations) fusion genes were obtained by artificial synthesis, and the 5' and 3' ends of the synthesized fragments each had a restriction enzyme e...

Embodiment 2

[0087] Example 2. Expression of fusion proteins in transfected cell lines

[0088] Transfection of recombinant expression vector plasmids into mammalian host cell lines to express hAT-L-vFc γ fusion protein. For stable high-level expression, the preferred host cell line is DHFR enzyme-deficient CHO-cells (US Patent No. 4,818,679). A preferred method of transfection is electroporation, although other methods including calcium phosphate co-sedimentation, lipofection, and protoplast fusion can also be used. In electroporation, use the Gene Pulser Electroporator (Bio-Rad Laboratories, Hercules, CA) set to 250V electric field and 960μFd capacitance, 2~5×10 7 Add 10 μg of plasmid DNA linearized with PvuI to each cell. Two days after transfection, the medium was changed to growth medium containing 0.4 mg / mL G418. Transfectants were screened for resistance to the selective drug using an anti-human IgG Fc ELISA assay. ELISA for anti-AT analysis can also be used to quantify the ex...

Embodiment 3

[0090] Example 3. Production of fusion proteins

[0091] The high-yield cell line preferably obtained in Example 2 is first subjected to serum-free acclimation culture in a petri dish, and then transferred to a shake flask for suspension acclimatization culture. After the cells have adapted to these culture conditions, they are then cultured in 300 ml shake flasks with fed supplementation. The above-mentioned CHO-derived cell lines were cultured in 100 ml shake flasks for 16 days, and the cumulative production of recombinant fusion proteins expressed by them was 2 g / L ( image 3 ). Between day 6 and day 12 of cell culture, the number of viable cells was at most about 7×10 6 individual / mL. In order to obtain more hAT-L-vFc recombinant protein, 2000 ml shake flask culture can also be selected.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a recombinant dimerized antithrombin III-Fc fusion protein, which has similar or higher biological activity in vitro and prolonged half-life in vivo than plasma-derived antithrombin III. The fusion protein provided by the present invention contains human antithrombin III (hAT), a flexible peptide linker (L) of about 20 amino acids or less, and a human IgG Fc variant (vFc) (expressed as hAT-L- vFc) (Fc). This Fc variant is non-lytic and shows minimal adverse Fc-mediated side effects. Such hAT-L-vFc fusion protein exhibits prolonged serum half-life and increased biological activity, thereby improving pharmacokinetics and efficacy. The invention also discloses a method for highly expressing or producing this kind of recombinant fusion protein by using mammalian cells.

Description

[0001] The present invention is a divisional application, the original application number is 2012101468630, the application date is May 14, 2012, and the title of the invention is "recombinant dimerized antithrombin III-Fc fusion protein and its high-efficiency expression in mammalian cells system". technical field [0002] The present invention relates to a recombinant dimerized Fc fusion protein of antithrombin III, its preparation method and its medical application, especially in the treatment of various coagulation-related diseases, anti-angiogenesis, anti-inflammation and anti-virus aspects of use. Background technique [0003] Anticoagulant system is the anticoagulant system that antagonizes the function of coagulation system in the human body. Under normal circumstances, the two maintain a dynamic balance. Antithrombin III (AT) is an important anticoagulant factor in human plasma, which bears 70% of the physiological antithrombin activity in plasma (Johnson DJ et al....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/85C12N5/10A61K38/57A61K47/48A61P7/04
Inventor 李强周若芸孙乃超
Owner AMPSOURCE BIOPHARMA (SHANGHAI) INC